logo

Axsome Therapeutics, Inc. (AXSM)



Trade AXSM now with
  Date
  Headline
10/21/2019 7:08:44 AM Axsome Therapeutics Completes Patient Enrollment In CONCERT Study
10/16/2019 7:07:17 AM Axsome Therapeutics Completes Patient Enrollment In GEMINI Phase 3 Trial Of AXS-05 In Major Depressive Disorder
10/2/2019 7:10:56 AM Axsome Therapeutics To Provide Update On Continued Progress At 2019 Cantor Global Healthcare Conference
9/5/2019 7:11:07 AM Axsome To Present Positive Results From Phase 1 Pharmacokinetic Trial Of AXS-07
6/7/2019 7:05:18 AM Axsome Therapeutics Provides Update On Continued Progress At Annual Stockholders’ Meeting
3/27/2019 7:09:53 AM Axsome Therapeutics Receives FDA Breakthrough Therapy Designation For AXS-05 For Major Depressive Disorder
2/6/2019 7:10:18 AM Axsome Therapeutics Receives FDA Agreement Under SPA For MOMENTUM Phase 3 Trial Of AXS-07 In Migraine
1/30/2019 7:11:26 AM Axsome Therapeutics Begins Phase 2 Trial Of AXS-12 In Narcolepsy; Expects Topline Results In Q2'19
1/7/2019 6:04:02 AM Axsome Therapeutics Unveils AXS-05 Achieves Primary Endpoint In Phase 2 Trial In Major Depressive Disorder
  
 
>